UnknownPhase 1NCT02637531
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
Studying Adrenocortical carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Infinity Pharmaceuticals, Inc.
- Principal Investigator
- Feng Chi, MDInfinity Pharmaceutical, Inc.
- Intervention
- IPI-549 (eganelisib)(drug)
- Enrollment
- 219 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2022
Study locations (11)
- UCSD, San Diego, California, United States
- UCLA, Santa Monica, California, United States
- Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie, Florida, United States
- Emory University, Atlanta, Georgia, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Hackensack University Medical Center, Hackensack, New Jersey, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- South Texas Accelerated Research and Treatment (START), San Antonio, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02637531 on ClinicalTrials.govOther trials for Adrenocortical carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06487481Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical CarcinomaNational Cancer Institute (NCI)
- RECRUITINGPHASE1NCT07189403A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate CancerDaiichi Sankyo
- RECRUITINGPHASE2NCT06587802Phase II Study of PD-1 Antibody Combined With Radiotherapy in Recurrent or Metastatic Adrenal Cortical CarcinomaSun Yat-sen University
- RECRUITINGNCT06279442Adrenal Project: Clinical and Epidemiological Characterization of Adrenocortical Carcinoma in a Brazilian CohortLatin American Cooperative Oncology Group
- RECRUITINGPHASE2NCT06333314Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSIUNICANCER
- RECRUITINGPHASE2NCT06066333Study of Radiotherapy and Pembrolizumab in People With Adrenocortical CarcinomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE2NCT05563467Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.Maria Sklodowska-Curie National Research Institute of Oncology
- RECRUITINGPHASE2NCT05913427Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia